1-甲基-2H-吡啶 | 33707-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-甲基-2H-吡啶
• 英文名称: 1-methyl-1,2-dihydropyridine
• 英文别名: N-methyl-1,2-dihydropyridine；N-methylpyridine；1-methyl-1,2-dihydro-pyridine；1-Methyl-1,2-dihydro-pyridin；N-Methyl-1,2-dihydropyridin；1-methyl-2H-pyridine
• CAS: 33707-38-9
• 化学式: C₆H₉N
• 分子量: 95.1442
• InChiKey: HZONRRHNQILCNO-UHFFFAOYSA-N

物化性质

• 沸点：
  148.2±10.0 °C(Predicted)
• 密度：
  0.913±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-甲基-2H-吡啶 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 乙醚 为溶剂， 25.0 ℃ 、241.32 kPa 条件下， 反应 12.0h， 生成 1-methylpiperidylidene-2-(2-pyridyl)sulfonamide
  参考文献：
  名称：

  Synthesis and antinociceptive activity of 1-methylpiperidylidene-2-(pyridyl)sulfonamides and related dihydropyridyl analogs

  摘要：

  The regiospecific 1,3-dipolar cycloaddition reaction of 1-methyl-1,2-dihydropyridine 2 with 2-, 3- or 4-pyridylsulfonyl azide 3a-c yielded the respective 1-methyl-1,2,3,6-tetrahydropyridylidene-2-(2-, 3- or 4-pyridyl)sulfonamides 5a-c. Hydrogenation of 5a-c afforded the corresponding 1-methylpiperldylidene-2-(pyridyl)sulfonamides 1a-c. Compounds lb and 1c were elaborated to 1',6'- 6a-d and 1',4'- 7a-c, and 1',2'-dihydropyridines 8a-e, respectively by quaternization with phenyl chloroformate followed by in situ reaction with methyl-, n-butyl-, t-butyl- or phenylmagnesium chloride, or sodium borohydride. Antinociceptive activity was determined using the rat sodium chloride-induced writhing assay. The point of attachment of the pyridyl ring was a determinant of activity where the relative activity order was 2-pyridyl la greater-than-or-equal-to 4-pyridyl 1c > 3-pyridyl 1b (ED50) values of 6.2, 9.0 and 6.6 mg/kg sc, respectively), relative to the reference drug meperidine (EC50 = 0.6 mg/kg sc). The pyridyl compounds lb,1c were more potent than their dihydropyridyl derivatives 6a-d, 8a-e. The most active dihydropyridyl derivative, 1-methylpiperidylidene-2-(1',2'-dihydro-2'-t-butyl-1'-phenoxycarbonyl-4'-pyridyl)sulfonamide 8c was more active at 25 mg/kg sc (68% inhibition of writhing) than aspirin at 50 mg/kg sc (58% inhibition of writhing). In the dihydropyridyl series of compounds 6a-d, 8a-e, a t-Bu substituent at the alpha-position of the 1',6'- or 1',2'-dihydropyridyl ring provided superior antinociceptive activity relative to that of a H, Me. n-Bu or Ph substituent.

  DOI：

  10.1016/0223-5234(93)90012-4
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 、 水 作用下， 生成 1-甲基-2H-吡啶
  参考文献：
  名称：

  Decker, Chemische Berichte, 1892, vol. 25, p. 3326

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-氯-3-磺酰胺基苯甲酸 、 叔-丁基氯甲酸酯 在 1-甲基-2H-吡啶 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  一种吲达帕胺的合成方法

  摘要：

  本发明涉及一种高质量吲达帕胺的制备方法，特别是涉及反应易控制、成本低、收率高的制备方法，属于原料药生产技术领域。本发明改变了反应的路径，使4-氯-3-氨磺酰基苯甲酸先和氯甲酸叔丁酯反应生成混合酸酐，然后再和N-氨基-2-甲基吲哚啉盐酸盐反应，省去了氯化亚砜酰氯化反应，提高了安全性，减少了对环境和设备的污染和腐蚀性，成本降低。收率较传统工艺收率可显著提高。

  公开号：

  CN105418479A

文献信息

• Tungsten(0) alkylidene complexes stabilized as pyridinium ylides: new aspects of their synthesis and reactivity
  作者：Henri Rudler、Thomas Durand-Réville

  DOI：10.1016/s0022-328x(00)00727-0

  日期：2001.1

  The interaction of dihydropyridines with alkoxycarbene complexes of tungsten has been shown to lead to pyridinium ylid complexes: this transformation has now been applied to the synthesis of a hydroxyl-containing ylid complex by ring-opening of the pentacarbonyl (2-oxacyclopentylidene) tungsten(0) complex and to the synthesis of a series of chiral ylid complexes both from chiral and non-chiral carbene

  二氢吡啶与钨的烷氧基卡宾配合物的相互作用已显示出吡啶基吡啶配合物：该转化现已应用于通过五羰基（2-氧杂环戊叉基）钨（0的开环）合成含羟基的吡啶配合物）并通过分别使用二氢吡啶和二苯并噻吩从手性和非手性卡宾配合物合成一系列手性碘配合物。这些配合物的亚烷基部分向亲核烯烃的转移将被概述和讨论。这些吡啶鎓碘化物络合物与不饱和底物（如二氢吡啶，烯胺和β-烷氧基双（三甲基甲硅烷基）乙烯酮缩醛）的相互作用尤其相关。后一反应生成共轭羧酸，
• Quaternary ammonium compounds having muscle relaxation activity
  申请人：Tobishi Yakuhin Kogyo Kabushiki Kaisha

  公开号：US05093370A1

  公开（公告）日：1992-03-03

  A quaternary ammonium having a muscle relaxation activity compound represented by the formula (I): ##STR1## wherein R.sub.1 represents a methylene, a lower alkylenoxy, a lower alkenylene, a lower alkynylene, --CO--, --COO--, a lower alkylene carbonyloxy, --CH(OR.sub.5)--, a lower alkylenecarbonyl, a hydroxy lower alkylene, --O--, --S--, --SO--, or --SO.sub.2 --; R.sub.2 represents a hydrogen atom, a hydroxy lower alkyl, an aldehyde, a lower alkyl carbonyl, --NO.sub.2, or --NHR.sub.6 ; R.sub.3 represents a hydrogen atom of a group --R.sub.1 --(CH.sub.2).sub.a --[CH(CH.sub.2 A)--CH.sub.2 ].sub.b --A; R.sub.4 represents an anion; R.sub.5 and R.sub.6 represent a hydrogen atom or a acetyl; A represents a quaternary ammonium group; a represents an integer of 1 to 8; b represents 0 or 1; m represents an integer of 1 to 4; and (Z) represents a trivalent benzene ring, a trivalent naphthalene ring, a trivalent diphenyl or a trivalent ethane radical.

  一种具有肌肉松弛活性的四价铵化合物，其化学式表示为(I)：##STR1## 其中R.sub.1表示亚甲基，较低的烷氧基，较低的烯基，较低的炔基，-CO-，-COO-，较低的烷基碳酸酯，-CH（OR.sub.5）-，较低的烷基羰基，羟基较低的烷基，-O-，-S-，-SO-，或-SO.sub.2-; R.sub.2表示氢原子，羟基较低烷基，醛，较低烷基羰基，-NO.sub.2或-NHR.sub.6; R.sub.3表示一羟基原子，属于一群-R.sub.1-(CH.sub.2).sub.a-[CH(CH.sub.2 A)-CH.sub.2].sub.b-A的氢原子; R.sub.4表示一个阴离子; R.sub.5和R.sub.6表示一个氢原子或一个乙酰基; A表示一个四价铵基团; a表示1到8的整数; b表示0或1; m表示1到4的整数; (Z)表示三价苯环，三价萘环，三价二苯基或三价乙烷基团。
• PI3 kinase modulators and methods of use
  申请人：Booker Shon

  公开号：US20090054405A1

  公开（公告）日：2009-02-26

  The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A 1 , A 2 , A 3 , A 4 , X, R 1 and R 2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，能够调节PI3激酶的活性，因此对于治疗PI3激酶介导的疾病，包括黑色素瘤、癌瘤和其他与癌症相关的疾病非常有用。这些化合物具有通式I，其中A1、A2、A3、A4、X、R1和R2均在此定义。本发明还涉及制药组合物、治疗PI3激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。
• IMINO COMPOUNDS AS PROTECTING AGENTS AGAINTS ULTRAVIOLET RADIATIONS
  申请人：Elkimia

  公开号：US20150152046A1

  公开（公告）日：2015-06-04

  The present invention relates to compounds having the general Formula I: which absorb UV radiations and protect biological materials as well as non-biological materials from damaging exposure to UV radiations. The present invention also relates to formulations and compositions comprising such compounds for use in absorbing UV radiations and in protecting biological materials as well as non-biological materials against UV radiations.

  本发明涉及具有一般式I的化合物，其吸收紫外辐射并保护生物材料和非生物材料免受紫外辐射的损害。本发明还涉及包含这种化合物的配方和组合物，用于吸收紫外辐射并保护生物材料和非生物材料免受紫外辐射的损害。
• Ondrus, Theodore A.; Pednekar, Purushottam R.; Knaus, Edward E., Canadian Journal of Chemistry, 1985, vol. 63, p. 2362 - 2368
  作者：Ondrus, Theodore A.、Pednekar, Purushottam R.、Knaus, Edward E.

  DOI：——

  日期：——